You are here

Bioiberica renews its Profarma Plan rating, reaffirming its commitment to R&D in Spain

3 Mar 2020
  • The company maintains, for another year, the "Good” rating

The Ministry of Industry's PROFARMA Plan Committee has released its ratings for companies in the pharmaceutical sector. Within group A (companies with significant research activity with their own pharmaceutical production plant or basic or preclinical R&D centres), Bioiberica maintains, for another year, the "Good” rating.

The PROFARMA Plan is a Ministry of Industry, Trade, and Tourism programme to promote competitiveness in the pharmaceutical industry by modernising the industry and promoting activities with value-add, favouring a shift in the production model, and encouraging an improved balance of payments and gross domestic product. PROFARMA publicly recognises the effort put into and commitment to R&D of the leading companies in the sector, the development of new active principles, the patents derived from research and in search of wider markets, as well as their increased commitment to the development of the industrial structure and production activities.

Bioiberica is a worldwide leader in the life sciences sector, committed to improving the health and well-being of people, animals, and plants. It is the leading manufacturer of heparin's pharmaceutical active substance and the world bellwether in the research, production, and sale of other ingredients of animal origin like chondroitin sulphate, glucosamine, hyaluronic acid, native type II collagen, and thyroid.

Related News

14 Feb 2020
  • The papers describe the use of various raw materials in cell regeneration and their regulatory aspects
15 Apr 2019
  • The Profarma committee released their ratings for the pharmaceutical sector firms
  • Bioiberica keeps the “good” rating within the A Group (those companies with significant research activity and having their own production plant or basic/pre-clinical R&D center)